Fulltext

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

Cardoso F 1 , Paluch-Shimon S 2 , Senkus E 3 , Curigliano G 4 , Aapro MS 5 , André F 6 Show all authors , Barrios CH 7 , Bergh J 8 , Bhattacharyya GS 9 , Biganzoli L 10 , Boyle F 11 , Cardoso MJ 12 , Carey LA 13 , Cortés J 14 , El Saghir NS 15 , Elzayat M 16 , Eniu A 17 , Fallowfield L 18 , Francis PA 19 , Gelmon K 20 , Gligorov J 21 , Haidinger R 22 , Harbeck N 23 , Hu X 24 , Kaufman B 25 , Kaur R 26 , Kiely BE 27 , Kim SB 28 , Lin NU 29 , Mertz SA 30 , Neciosup S 31 , Offersen BV 32 , Ohno S 33 , Pagani O 34 , Prat A 35 , Penault-Llorca F 36 , Rugo HS 37 , Sledge GW 38 , Thomssen C 39 , Vorobiof DA 40 , Wiseman T 41 , Xu B 42 , Norton L 43 , Costa A 44 , Winer EP 29

Affiliations 

  • 1 Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal. Electronic address: fatimacardoso@fundacaochampalimaud.pt
  • 2 Sharett Division of Oncology, Hadassah University Hospital, Jerusalem, Israel
  • 3 Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
  • 4 Department of Oncology and Hemato-Oncology, European Institute of Oncology, IRCCS, Division of Early Drug Development, University of Milan, Milan, Italy
  • 5 Breast Center, Clinique de Genolier, Genolier, Switzerland
  • 6 Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
  • 7 Latin American Cooperative Oncology Group (LACOG), Grupo Oncoclínicas, Porto Alegre, Brazil
  • 8 Department of Oncology-Pathology, Karolinska Institute & University Hospital, Stockholm, Sweden
  • 9 Department of Medical Oncology, Salt Lake City Medical Centre, Kolkata, India
  • 10 Department of Medical Oncology, Nuovo Ospedale di Prato - Istituto Toscano Tumori, Prato, Italy
  • 11 The Pam McLean Centre, Royal North Shore Hospital, St Leonards, Australia
  • 12 Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal; Nova Medical School, Lisbon, Portugal
  • 13 Department of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA
  • 14 IOB Institute of Oncology, Quiron Group, Madrid & Barcelona, Spain; Department of Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Spain
  • 15 Division of Hematology Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
  • 16 Europa Donna, The European Breast Cancer Coalition, Milan, Italy
  • 17 Interdisciplinary Oncology Service (SIC), Riviera-Chablais Hospital, Rennaz, Switzerland
  • 18 SHORE-C, Brighton & Sussex Medical School, University of Sussex, Brighton, UK
  • 19 Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
  • 20 Medical Oncology Department, BC Cancer Agency, Vancouver, Canada
  • 21 Breast Cancer Expert Center, University Cancer Institute APHP, Sorbonne University, Paris, France
  • 22 Brustkrebs Deutschland e.V., Munich, Germany
  • 23 Breast Centre, Department of Obstetrics and Gynaecology, University of Munich (LMU), Munich, Germany
  • 24 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
  • 25 Department of Oncology, Sheba Medical Center, Ramat Gan, Israel
  • 26 Breast Cancer Welfare Association Malaysia, Petaling Jaya, Malaysia
  • 27 NHMRC Clinical Trials Centre, Sydney Medical School, Sydney, Australia
  • 28 Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea
  • 29 Susan Smith Center for Women's Cancers - Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA
  • 30 Metastatic Breast Cancer Network, Inverness, USA
  • 31 Department of Medical Oncology, National Institute of Neoplastic Diseases, Lima, Peru
  • 32 Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
  • 33 Breast Oncology Centre, Cancer Institute Hospital, Tokyo, Japan
  • 34 Medical School, Geneva University Hospital, Geneva, Switzerland
  • 35 Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona; Department of Medicine, University of Barcelona, Barcelona
  • 36 Department of Biopathology, Centre Jean Perrin, Clermont-Ferrand, France; University Clermont Auvergne/INSERM U1240, Clermont-Ferrand, France
  • 37 Breast Oncology Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
  • 38 Division of Oncology, Stanford School of Medicine, Stanford, USA
  • 39 Department of Gynaecology, Martin Luther University Halle-Wittenburg, Halle, Germany
  • 40 Oncology Research Unit, Belong.Life, Tel Aviv, Israel
  • 41 Department of Applied Health Research in Cancer Care, The Royal Marsden Hospital NHS Foundation Trust, London, UK
  • 42 Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
  • 43 Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, USA
  • 44 European School of Oncology, Milan, Italy; European School of Oncology, Bellinzona, Switzerland
Ann Oncol, 2020 Dec;31(12):1623-1649.
PMID: 32979513 DOI: 10.1016/j.annonc.2020.09.010

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications